Hypovascular nodules in patients with chronic liver disease: Risk factors for development of hypervascular hepatocellular carcinoma

Radiology

Volumn 266, Issue 2, 2013, Pages 480-490

  Hyodo, Tomoko ^a,e   Murakami, Takamichi ^a   Imai, Yasuharu ^b   Okada, Masahiro ^a   Hori, Masatoshi ^c   Kagawa, Yuki ^a   Kogita, Sachiyo ^b   Kumano, Seishi ^d   Kudo, Masatoshi ^a   Mochizuki, Teruhito ^e  

^a KINKI UNIVERSITY   (Japan)

^b Ikeda Municipal Hospital   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d OSAKA MEDICAL COLLEGE   (Japan)

^e EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GADOXETIC ACID;

ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; CONTRAST ENHANCEMENT; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; DISEASE PROGRESSION; END STAGE LIVER DISEASE; FEMALE; GADOLINIUM DTPA; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84873335816     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12112677     Document Type: Article

References (40)

1. Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008;247(2):311-330.
2. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53(3):1020-1022.
3. Giovagnoni A, Paci E. Liver. III: Gadoliniumbased hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Magn Reson Imaging Clin N Am 1996;4(1):61-72.
4. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U. S. multicenter phase III study. Radiology 2005;237(1):89-98.
5. Haradome H, Grazioli L, Tinti R, et al. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triplephase multidetector CT imaging. J Magn Reson Imaging 2011;34(1):69-78.
6. Okada M, Imai Y, Kim T, et al. Comparison of enhancement patterns of histologically confrmed hepatocellular carcinoma between gadoxetate-and ferucarbotranenhanced magnetic resonance imaging. J Magn Reson Imaging 2010;32(4):903-913.
7. Lee VS, Lavelle MT, Rofsky NM, et al. Hepatic MR imaging with a dynamic contrastenhanced isotropic volumetric interpolated breath-hold examination: feasibility, reproducibility, and technical quality. Radiology 2000;215(2):365-372.
8. Golferi R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤2 cm) HCC in cirrhosis. Eur Radiol 2011;21(6):1233-1242.
9. International Consensus Group for Hepatocellular Neoplasia The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49(2):658-664.
10. Hayashi M, Matsui O, Ueda K, et al. Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. AJR Am J Roentgenol 1999;172(4):969-976.
11. Yu JS, Chung JJ, Kim JH, Kim KW. Fatcontaining nodules in the cirrhotic liver: chemical shift MRI features and clinical implications. AJR Am J Roentgenol 2007;188(4):1009-1016.
12. Motosugi U, Ichikawa T, Sano K, et al. Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging 2011;34(1):88-94.
13. Kumada T, Toyoda H, Tada T, et al. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol 2011;197(1):58-63.
14. Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991;22(2):172-178.
15. Makuuchi M, Kokudo N, Arii S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008;38(1):37-51.
16. Kagawa Y, Okada M, Kumano S, et al. Optimal scanning protocol of arterial dominant phase for hypervascular hepatocellular carcinoma with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR. J Magn Reson Imaging 2011;33(4):864-872.
17. Goshima S, Kanematsu M, Kondo H, et al. MDCT of the liver and hypervascular hepatocellular carcinomas: optimizing scan delays for bolus-tracking techniques of hepatic arterial and portal venous phases. AJR Am J Roentgenol 2006;187(1):W25-W32.
18. Hori M, Murakami T, Kim T, Nakamura H. Diagnosis of hepatic neoplasms using CT arterial portography and CT hepatic arteriography. Tech Vasc Interv Radiol 2002;5(3):164-169.
19. Kudo M, Hatanaka K, Maekawa K. Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using sonazoid in the management of hepatocellular carcinoma. Oncology 2010;78(Suppl 1):40-45.
20. Collins VP, Loeffer RK, Tivey H. Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med 1956;76(5):988-1000.
21. Schwartz M. A biomathematical approach to clinical tumor growth. Cancer 1961;14:1272-1294.
22. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2010.
23. Lin DY. Cox regression analysis of multivariate failure time data: the marginal approach. Stat Med 1994;13(21):2233-2247.
24. Fawcett T. An introduction to ROC analysis. Pattern Recognit Lett 2006;27(8):861-874.
25. Kadoya M, Matsui O, Takashima T, Nonomura A. Hepatocellular carcinoma: correlation of MR imaging and histopathologic fndings. Radiology 1992;183(3):819-825.
26. Ohtomo K, Baron RL, Dodd GD 3rd, Federle MP, Ohtomo Y, Confer SR. Confuent hepatic fibrosis in advanced cirrhosis: evaluation with MR imaging. Radiology 1993;189(3):871-874.
27. Kim T, Baron RL, Nalesnik MA. Inflarcted regenerative nodules in cirrhosis: CT and MR imaging fndings with pathologic correlation. AJR Am J Roentgenol 2000;175(4):1121-1125.
28. Hussain HK, Syed I, Nghiem H V, et al. T2-weighted MR imaging in the assessment of cirrhotic liver. Radiology 2004;230(3):637-644.
29. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5, Suppl 1):S35-S50.
30. Bolondi L, Sofa S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48(2):251-259.
31. Rozario R, Ramakrishna B. Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems. J Hepatol 2003;38(2):223-229.
32. Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 2005;32(3):173-184.
33. Kobayashi S, Matsui O, Gabata T, et al. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic Acid-enhanced magnetic resonance imaging fndings of borderline lesions at high risk for progression to hypervascular classic hepatocellular carcinoma. J Comput Assist Tomogr 2011;35(2):181-186.
34. Ebara M, Fukuda H, Kojima Y, et al. Small hepatocellular carcinoma: relationship of signal intensity to histopathologic fndings and metal content of the tumor and surrounding hepatic parenchyma. Radiology 1999;210(1):81-88.
35. Basaran C, Karcaaltincaba M, Akata D, et al. Fat-containing lesions of the liver: cross-sectional imaging fndings with emphasis on MRI. AJR Am J Roentgenol 2005;184(4):1103-1110.
36. Jeong YY, Mitchell DG, Kamishima T. Small (, 20 mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: clinical implications. AJR Am J Roentgenol 2002;178(6):1327-1334.
37. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42(5):1208-1236.
38. Zech CJ, Vos B, Nordell A, et al. Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol 2009;44(6):305-310.
39. Chung SH, Kim MJ, Choi JY, Hong HS. Comparison of two different injection rates of gadoxetic acid for arterial phase MRI of the liver. J Magn Reson Imaging 2010;31(2):365-372.
40. Kim KA, Herigault G, Kim MJ, Chung YE, Hong HS, Choi SY. Three-dimensional contrast-enhanced hepatic MR imaging: comparison between a centric technique and a linear approach with partial Fourier along both slice and phase directions. J Magn Reson Imaging 2011;33(1):160-166.